DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

Phase 4

Completed

Conditions: Hypogonadism
Cardiovascular Diseases

Interventions: Drug: AndroGel®
Drug: Placebo

First Posted Date: 2018-05-08

Last Posted Date: 2024-03-13

Lead Sponsor: AbbVie

Target Recruit Count: 5246

Registration Number: NCT03518034

Locations: 🇺🇸
Founders Research Corp /ID# 170610, Philadelphia, Pennsylvania, United States
🇺🇸
Alliance for Multispecialty Research- Norman /ID# 170581, Norman, Oklahoma, United States
🇺🇸
Maryland Cardiovascular Specialists /ID# 168057, Baltimore, Maryland, United States

and more 381 locations

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: risankizumab
Drug: placebo for rizankizumab

First Posted Date: 2018-05-08

Last Posted Date: 2021-01-25

Lead Sponsor: AbbVie

Target Recruit Count: 50

Registration Number: NCT03518047

Locations: 🇷🇺
GBUZ Clinical Dermatovenerology Dispensary of MoH of Krasnodar region /ID# 201713, Krasnodar, Krasnodarskiy Kray, Russian Federation
🇷🇺
LLC Kurator /ID# 200616, Saint-Petersburg, Sankt-Peterburg, Russian Federation
🇷🇺
Alliance Biomedical Ural Group /ID# 201681, Izhevsk, Udmurtskaya Respublika, Russian Federation

and more 3 locations

A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)

Completed

Conditions: Ankylosing Spondylitis (AS)

First Posted Date: 2018-04-23

Last Posted Date: 2023-07-20

Lead Sponsor: AbbVie

Target Recruit Count: 28

Registration Number: NCT03505892

Locations: 🇨🇳
Hualien Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation, Hualien City, Taiwan

Expanded Access to Rovalpituzumab Tesirine

Conditions: Small Cell Lung Cancer

First Posted Date: 2018-04-20

Last Posted Date: 2019-09-10

Lead Sponsor: AbbVie

Registration Number: NCT03503890

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Cancer - Acute Myeloid Leukemia

Interventions: Drug: Venetoclax
Drug: Dinaciclib

First Posted Date: 2018-03-30

Last Posted Date: 2022-12-30

Lead Sponsor: AbbVie

Target Recruit Count: 48

Registration Number: NCT03484520

Locations: 🇺🇸
David Geffen School of Medicin /ID# 200015, Los Angeles, California, United States
🇺🇸
The Ohio State University /ID# 200668, Columbus, Ohio, United States
🇦🇺
Gold coast University Hospital /ID# 202759, SouthPort, Queensland, Australia

and more 10 locations

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: secukinumab
Drug: risankizumab

First Posted Date: 2018-03-27

Last Posted Date: 2021-07-13

Lead Sponsor: AbbVie

Target Recruit Count: 327

Registration Number: NCT03478787

Locations: 🇨🇦
Beacon Dermatology Inc /ID# 203054, Calgary, Alberta, Canada
🇫🇷
Hopital Saint-Louis /ID# 203586, Paris, France
🇺🇸
Progressive Medical Research /ID# 202183, Port Orange, Florida, United States

and more 58 locations

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Venetoclax
Drug: Alvocidib

First Posted Date: 2018-02-22

Last Posted Date: 2022-02-01

Lead Sponsor: AbbVie

Target Recruit Count: 36

Registration Number: NCT03441555

Locations: 🇩🇪
Univ Klinik Eppendorf Hamburg /ID# 168633, Hamburg, Germany
🇺🇸
NYU Langone Medical Center /ID# 201559, New York, New York, United States
🇺🇸
University of Pittsburgh Medic /ID# 170790, Pittsburgh, Pennsylvania, United States

and more 11 locations

UNITE Study: Understanding New Interventions With GBM ThErapy

Phase 3

Terminated

Conditions: Glioblastoma Multiforme

Interventions: Drug: Steroid eye drops
Drug: Vasoconstrictor eye drops
Drug: Depatuxizumab mafodotin
Other: Cold compress
Drug: Temozolomide
Radiation: Radiation
Drug: Ophthalmic steroid ointment

First Posted Date: 2018-02-05

Last Posted Date: 2021-04-14

Lead Sponsor: AbbVie

Target Recruit Count: 40

Registration Number: NCT03419403

Locations: 🇩🇪
Universitatsklinikum Tubingen /ID# 169965, Tuebingen, Germany
🇺🇸
Levine Cancer Ins, Carolina Me /ID# 171271, Charlotte, North Carolina, United States
🇳🇱
Vrije Universiteit Medisch Centrum /ID# 170152, Amsterdam, Netherlands

and more 19 locations

Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia

Active, not recruiting

Conditions: Cancer - Chronic Lymphocytic Leukemia

First Posted Date: 2018-01-30

Last Posted Date: 2024-06-17

Lead Sponsor: AbbVie

Target Recruit Count: 269

Registration Number: NCT03415035

Locations: 🇫🇷
Ch Agen /Id# 170742, Agen Cedex 9, France
🇫🇷
CH Victor Dupouy /ID# 169946, Argenteuil, France
🇫🇷
CH Libourne - Hopital Robert Boulin /ID# 170739, Libourne, France

and more 57 locations

Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

Phase 1

Completed

Conditions: Progressive Supranuclear Palsy (PSP)

Interventions: Drug: ABBV-8E12

First Posted Date: 2018-01-29

Last Posted Date: 2019-12-03

Lead Sponsor: AbbVie

Target Recruit Count: 3

Registration Number: NCT03413319

Locations: 🇺🇸
University of California, San /ID# 170113, La Jolla, California, United States
🇺🇸
Texas Health Physicians Group /ID# 170112, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy